Principia Biopharma Inc (NASDAQ:PRNB) has received a consensus broker rating score of 1.00 (Strong Buy) from the five analysts that cover the stock, Zacks Investment Research reports. Five investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1 year consensus price objective of $43.00 for the company and are forecasting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also given Principia Biopharma an industry rank of 46 out of 255 based on the ratings given to related companies.

A number of equities research analysts have recently commented on PRNB shares. Zacks Investment Research lowered Principia Biopharma from a “buy” rating to a “sell” rating in a research report on Wednesday, January 9th. Stifel Nicolaus started coverage on Principia Biopharma in a research report on Tuesday. They set a “buy” rating and a $45.00 price target on the stock. Finally, Leerink Swann set a $42.00 price target on Principia Biopharma and gave the stock a “buy” rating in a research report on Thursday, March 21st.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of Principia Biopharma by 61.1% during the 4th quarter. FMR LLC now owns 1,142,071 shares of the company’s stock worth $31,281,000 after acquiring an additional 433,194 shares during the period. BlackRock Inc. boosted its stake in shares of Principia Biopharma by 196.1% during the 4th quarter. BlackRock Inc. now owns 442,666 shares of the company’s stock worth $12,125,000 after acquiring an additional 293,166 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Principia Biopharma by 2.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 230,406 shares of the company’s stock worth $6,311,000 after acquiring an additional 4,844 shares during the period. Franklin Resources Inc. bought a new position in shares of Principia Biopharma during the 3rd quarter worth approximately $6,575,000. Finally, Geode Capital Management LLC bought a new position in shares of Principia Biopharma during the 4th quarter worth approximately $3,056,000. 81.91% of the stock is currently owned by institutional investors.

NASDAQ:PRNB traded up $0.66 during mid-day trading on Friday, hitting $29.67. The company had a trading volume of 2,858 shares, compared to its average volume of 96,808. Principia Biopharma has a fifty-two week low of $22.00 and a fifty-two week high of $38.34. The firm has a market capitalization of $692.32 million and a price-to-earnings ratio of 51.67.

Principia Biopharma (NASDAQ:PRNB) last released its earnings results on Tuesday, March 19th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.68. The company had revenue of $26.14 million during the quarter, compared to analyst estimates of $13.70 million. As a group, sell-side analysts expect that Principia Biopharma will post -2.51 EPS for the current year.

Principia Biopharma Company Profile

Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.

Featured Article: What is a blue-chip stock?

Get a free copy of the Zacks research report on Principia Biopharma (PRNB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Principia Biopharma (NASDAQ:PRNB)

Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.